WA
PCRX icon

WFG Advisors’s Pacira BioSciences PCRX Stock Holding History

WFG Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$5K Hold
100
– – ﹤0.01% 1289
2017
Q1 		$5K Hold
100
– – ﹤0.01% 1224
2016
Q4 		$3K Hold
100
– – ﹤0.01% 1364
2016
Q3 		$3K Hold
100
– – ﹤0.01% 1355
2016
Q2 		$3K Hold
100
– – ﹤0.01% 1333
2016
Q1 		$5K Sell
100
-200
-67% -$11.7K ﹤0.01% 1197
2015
Q4 		$23K Hold
300
– – 0.01% 857
2015
Q3 		$12K Buy
+300
New +$18.4K ﹤0.01% 1049
2015
Q1 		– Sell
-150
Closed -$13K – 1986
2014
Q4 		$13K Hold
150
– – ﹤0.01% 1368
2014
Q3 		$15K Buy
150
+50
+50% +$4.86K ﹤0.01% 1375
2014
Q2 		$9K Sell
100
-607
-86% -$46.2K ﹤0.01% 1523
2014
Q1 		$49K Buy
707
+100
+16% +$6.8K 0.01% 914
2013
Q4 		$35K Hold
607
– – 0.01% 1131
2013
Q3 		$29K Buy
607
+100
+20% +$3.64K ﹤0.01% 1120
2013
Q2 		$15K Buy
+507
New +$14.7K ﹤0.01% 1322

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

WFG Advisors's PCRX Position: Q2 2017 in Review

WFG Advisors held its Pacira BioSciences (PCRX) position steady in Q2 2017 at 100 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1289.

WFG Advisors first reported a position in PCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $49K in Q1 2014. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • WFG Advisors held 100 shares of Pacira BioSciences worth $5K as of Q2 2017.
  • WFG Advisors left its Pacira BioSciences share count unchanged in Q2 2017.
  • Pacira BioSciences made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1289 holding.
  • WFG Advisors first reported a position in Pacira BioSciences in Q2 2013 and has held it in 15 quarters since.
  • WFG Advisors's Pacira BioSciences position peaked at $49K in Q1 2014.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.